Gyrodyne , LLC (NASDAQ:GYRO) Short Interest Up 1,646.7% in March

Gyrodyne , LLC (NASDAQ:GYRO) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 786 shares, a growth of 1,646.7% from the March 15th total of 45 shares. Based on an average trading volume of 793 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.0% of the shares of the stock are short sold.

Gyrodyne Trading Up 1.8%

NASDAQ GYRO opened at $8.13 on Friday. Gyrodyne has a 12 month low of $7.55 and a 12 month high of $12.00. The company’s 50 day simple moving average is $8.49 and its 200 day simple moving average is $9.17.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Bulldog Investors LLP acquired a new position in shares of Gyrodyne during the third quarter valued at approximately $601,000. Teton Advisors LLC acquired a new position in shares of Gyrodyne during the third quarter valued at approximately $177,000. Susquehanna International Group LLP acquired a new position in shares of Gyrodyne during the third quarter valued at approximately $142,000. Finally, Advisory Services Network LLC acquired a new position in shares of Gyrodyne during the third quarter valued at approximately $77,000. Institutional investors and hedge funds own 71.36% of the company’s stock.

Gyrodyne Company Profile

Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.

The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.